幽门螺旋杆菌概念股继续走强，亚太药业2连板，均瑶健康触及涨停，科拓生物、东诚药业跟涨。

Like
Comment
Favorite

幽门螺旋杆菌概念股继续走强，亚太药业2连板，均瑶健康触及涨停，科拓生物、东诚药业跟涨。

华尔街见闻2022-01-07

幽门螺旋杆菌概念股继续走强，亚太药业2连板，均瑶健康触及涨停，科拓生物、东诚药业跟涨。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2201529972?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2022-01-07 09:30","share_image_url":"https://static.laohu8.com/cc96873d3d23ee6ac10685520df9c100","id":"2201529972","market":"sh","top_or_hot":-1,"title":"幽门螺旋杆菌概念股继续走强，亚太药业2连板，均瑶健康触及涨停，科拓生物、东诚药业跟涨。","media":"华尔街见闻","content":"<div>\n<p>幽门螺旋杆菌概念股继续走强，亚太药业2连板，均瑶健康触及涨停，科拓生物、东诚药业跟涨。</p>\n\n<a href=\"https://wallstreetcn.com/live/a-stock\">Source Link</a>\n\n</div>\n","source":"live_wallstreetcn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7x24快讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7x24快讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 09:30 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/live/a-stock><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>幽门螺旋杆菌概念股继续走强，亚太药业2连板，均瑶健康触及涨停，科拓生物、东诚药业跟涨。</p>\n\n<a href=\"https://wallstreetcn.com/live/a-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002370","symbol_name":"亚太药业","start_time":0,"source_url":"https://wallstreetcn.com/live/a-stock","article_id":"2201529972","we_media_id":null,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2201529972","pubTimestamp":1641519056,"columns":[],"sourceInfo":{"source_id":"live_wallstreetcn","name":"华尔街见闻"},"weMediaInfo":null,"summary":"幽门螺旋杆菌概念股继续走强，亚太药业2连板，均瑶健康触及涨停，科拓生物、东诚药业跟涨。","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300858":"科拓生物","605388":"均瑶健康","002370":"亚太药业","002675":"东诚药业"},"translate_title":"Helicobacter pylori concept stocks continued to strengthen, Asia-Pacific Pharmaceutical had 2 consecutive boards, Juneyao Health hit the daily limit, Ketuo Biotech and Dongcheng Pharmaceutical followed suit.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300858":1,"605388":1,"002370":1,"002675":1},"content_text":"幽门螺旋杆菌概念股继续走强，亚太药业2连板，均瑶健康触及涨停，科拓生物、东诚药业跟涨。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}